Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 8/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.36 |
| ▸ | GCGR | P47871 | 6/20 | 0.36 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.36 |
| ▸ | TXN | P10599 | 1/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.36 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | HTR2C | P28335 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL527760 | 0.84 | ADORA1 (0.49) | ADORA1SCN9AADORA2BMAPK14GCGR | |
| SCHEMBL2339952 | 0.82 | ALOX5 (0.41) | SCN9AMAPK14GCGRMAPK13MAPK12 | |
| SCHEMBL2340032 | 0.82 | ADORA1 (0.48) | ADORA1SCN9AADORA2BMAPK14GCGR | |
| SCHEMBL2344474 | 0.82 | ADORA1 (0.48) | ADORA1SCN9AADORA2BMAPK14GCGR | |
| SCHEMBL2347107 | 0.81 | GCGR (0.42) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL16429685 | 0.81 | GCGR (0.57) | ADORA1SCN9AGCGR | |
| SCHEMBL7921907 | 0.80 | ADORA1 (0.46) | ADORA1SCN9AGCGR | |
| SCHEMBL3082 | 0.79 | ADORA1 (0.45) | ADORA1SCN9AGCGR | |
| SCHEMBL2340258 | 0.79 | GCGR (0.43) | MAPK14GCGRMAPK13MAPK12MAPK11 | |
| SCHEMBL2346398 | 0.79 | ADORA2A (0.45) | ADORA1SCN9AADORA2BMAPK14GCGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101084197-B | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD | 2012-06-13 | — | — | CN | claimed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | claimed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | claimed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | claimed |
| CN-101084197-A | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD (GB) | 2007-12-05 | — | — | CN | claimed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | claimed |
| CN-101084197-B | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD | 2012-06-13 | — | — | CN | disclosed |
| US-8034932-B2 | Hydroxy-3-methylglutaryl/3-/ coenzyme A reductase inhibitor; anticholesterol agents;dyslipidemia; chemical intermediate for rosuvastatin | ASTRAZENECA UK LIMITED (GB) | 2011-10-11 | — | — | US | disclosed |
| EP-2361906-A1 | Process for preparing rosuvastatin | AstraZeneca UK Limited (GB) | 2011-08-31 | — | — | EP | disclosed |
| US-20080207903-A1 | Chemical Process | ASTRAZENECA UK LIMITED (GB) | 2008-08-28 | — | — | US | disclosed |
| EP-1871747-A2 | PROCESS FOR PREPARING ROSUVASTATIN | AstraZeneca UK Limited (GB) | 2008-01-02 | — | — | EP | disclosed |
| CN-101084197-A | Process for the preparation of rosuvastatin | ASTRAZENECA UK LTD (GB) | 2007-12-05 | — | — | CN | disclosed |
| WO-2006067456-A2 | PROCESS FOR PREPARING ROSUVASTATIN | ASTRAZENECA UK LIMITED (GB) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207903-A1 | Chemical Process | CYP2C9, CYP2B6, CYP7A1 | ADORA1 4310/4885SCN9A 955/4885ADORA2B 4043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.